Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd versus Rd for high-risk smoldering multiple myeloma
NL-OMON59199Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carfilzomib, lenalidomide and dexamethasone in smoldering multiple myeloma (SMM) (2 arms), sponsored by HOVON. Started Nov 2018; status: active, not recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NL-OMON59199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59199.